1. bookVolume 2 (2019): Issue 1 (April 2019)
Journal Details
License
Format
Journal
eISSN
2601-9388
First Published
30 Sep 2018
Publication timeframe
2 times per year
Languages
English
access type Open Access

Cystic fibrosis related diabetes

Published Online: 04 May 2019
Volume & Issue: Volume 2 (2019) - Issue 1 (April 2019)
Page range: 23 - 27
Received: 02 Feb 2019
Accepted: 27 Feb 2019
Journal Details
License
Format
Journal
eISSN
2601-9388
First Published
30 Sep 2018
Publication timeframe
2 times per year
Languages
English
Abstract

Cystic fibrosis related diabetes (CFRD) is a redoubtable complication associated to cystic fibrosis, with an increasing frequency, directly proportional to children life expectancy. Although this complication has similar features with DM type 1 and some with type 2, the evolution and even the response to insulin therapy is different. It is also possible that other factors to influence the CFRD clinical expression and subsequently the disease evolution. Since its 1t diagnosis was associated with more frequent pulmonary exacerbations and with the deterioration of the respiratory status, therefore CFRD must be early and correctly diagnosed and managed. The aim of this paper is to present an overview of the recent updates and recommendations regarding this important CF complication.

Keywords

1. Southern KW, Munck A, Pollitt R, Travert G, Zanolla L, Dankert-Roelse J, et al. A survey of newborn screening for cystic fibrosis in Europe. J Cyst Fibros. 2007;6:57–65.10.1016/j.jcf.2006.05.008Search in Google Scholar

2. Popa I, Pop L, Popa Z, Schwarz MJ, Hambleton G, Malone GM, et al. Cystic fibrosis mutations in Romania. Eur J Pediatr. 1997;156:212–213.10.1007/s004310050586Search in Google Scholar

3. O’Sullivan BP, Freedman SD. Cystic fibrosis. Lancet. 2009 May;373(9678):1891–904.10.1016/S0140-6736(09)60327-5Search in Google Scholar

4. Ciuca IM, Pop L, Ranetti A., Popescu I.M, et all, Ursodeoxicholic acid effects on cystic fibrosis liver disease, Farmacia, 63: 543-547Search in Google Scholar

5. Ciuca IM, Pop LL, Rogobete AF, Onet DI, Guta-Almajan B, Popa Z, et al. Genetic Expression in Cystic Fibrosis Related Bone Disease. An Observational, Transversal, Cross-Sectional Study. Clin Lab. 2016;62(9):1725–30.Search in Google Scholar

6. Marshall BC, Butler SM, Stoddard M, Moran AM, Liou TG, Morgan WJ, et al. Epidemiology of cystic fibrosis-related diabetes. J Pediatr. 2005;146:681–68710.1016/j.jpeds.2004.12.039Search in Google Scholar

7. Moran A, Becker D, Casella SJ, Gottlieb PA, Kirkman MS, Marshall BC, et al. Epidemiology, pathophysiology, and prognostic implications of cystic fibrosis-related diabetes: A technical review. Diabetes Care. 2010;33:2677–2683.10.2337/dc10-1279Search in Google Scholar

8. Moran A, Pillay K, Becker DJ, Acerini CL. Management of cystic fibrosis-related diabetes in children and adolescents. Pediatr Diabetes. 2014;15:65–76.10.1111/pedi.12178Search in Google Scholar

9. Moran A, Brunzell C, Cohen RC, Katz M, Marshall BC, Onady G, et al. Clinical care guidelines for cystic fibrosis-related diabetes: A position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes Care. 2010;33:2697–2708.10.2337/dc10-1768Search in Google Scholar

10. Lanng S, Hansen A, Thorsteinsson B, Nerup J, Koch C. Glucose tolerance in patients with cystic fibrosis: five year prospective study. BMJ. 1995;311:655–65910.1136/bmj.311.7006.655Search in Google Scholar

11. Brunzell C., Hardin D.S., Kogler A., Moran A., Schindler T. Managing Cystic Fibrosis-Related Diabetets (CFRD) - An Instruction Guide for Patients and Families. Cystic Fibrosis Foundation. 2015; 10.Search in Google Scholar

12. Sinaasappel M, Stern M, Littlewood J, Wolfe S, Steinkamp G, Heijerman HGM, et al. Nutrition in patients with cystic fibrosis: A European Consensus. Vol. 1, J Cystic Fibros 2002; 1:51–7510.1016/S1569-1993(02)00032-2Search in Google Scholar

13. Engelen MPKJ, Com G, Deutz NEP. Protein is an important but undervalued macronutrient in the nutritional care of patients with cystic fibrosis. Vol. 17, Current Opinion in Clinical Nutrition and Metabolic Care, 2014;7:515–520.Search in Google Scholar

14. Gaskin KJ. Nutritional care in children with cystic fibrosis: Are our patients becoming better? Vol. 67, European Journal of Clinical Nutrition, 2013; 67 :558–56410.1038/ejcn.2013.2023462946Search in Google Scholar

15. Matel JL. Nutritional management of cystic fibrosis. Journal of Parenteral and Enteral Nutrition. 2012; 36: 60S-70S10.1177/014860711142015622237878Search in Google Scholar

16. Brunzell C., Hardin D.S., Kogler A., Moran A., Schindler T. Managing Cystic Fibrosis-Related Diabetets (CFRD) - An Instruction Guide for Patients and Families. Cystic Fibrosis Foundation. 2015; 35.Search in Google Scholar

17. Sunni M, Bellin MD, Moran A. Exogenous insulin requirements do not differ between youth and adults with cystic fi-brosis related diabetes. Pediatr Diabetes. 2013;14(4):295–29810.1111/pedi.12014375322423350702Search in Google Scholar

18. Moran A, Pekow P, Grover P, Zorn M, Slovis B, Pilewski J, et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: Results of the cystic fibrosis related diabetes therapy trial. Diabetes Care. 2009;32:1783–178810.2337/dc09-0585275294019592632Search in Google Scholar

19. Moran A, Pillay K, Becker D, Granados A, Hameed S, Acerini CL. ISPAD Clinical Practice Consensus Guidelines 2018: Management of cystic fibrosis-related diabetes in children and adolescents. Pediatr Diabetes. 2018;19: 64–7410.1111/pedi.1273230094886Search in Google Scholar

Recommended articles from Trend MD

Plan your remote conference with Sciendo